Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06756152 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Preventing of GVHD with Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Ruxolitinib At Children and Young Adults with Hemoblastosis

StatusRecruiting
PhasePhase 2/3
Started2024-07-10
View on ClinicalTrials.gov ↗
Record status
This record was last updated January 1, 2025 (before its estimated July 10, 2026 completion). Its status may not reflect the trial's current state.
GVHD prevention using a combination of post-transplantation cyclophosphamide in combination with abatacept, vedolizumab and Ruxolitinib in children and young adults with hematoloblastosis after myeloablative conditioning regimen with treosulfan/TBI, etoposide, fludarabine after HSCT from matched unrelated and haploidentical donors
Trial Details
NCT Number NCT06756152
Lead Sponsor Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Conditions Biphenotypic Acute Leukemia, Acute Lymphoblastic Leukemia, Myeloblastic Leukemia, Bilinear Leukemia, Malignant Lymphoma, Non-Hodgkin, Myelodysplastic Syndrome
Enrollment 50 participants
Start Date 2024-07-10
Primary Completion 2026-07-10 (estimated)
Study Completion 2026-10-10 (estimated)
Updated on ClinicalTrials.gov 2025-01-01